Hua?Medicine?(the?"Company",?HKEx?stock?code:?2552)?announced?today?that?the?Company?and?its?wholly-owned?subsidiary,?Nanjing?AscendRare?Pharmaceutical?Technology?Co.,?Ltd.(AscendRare),?presented?a?number?of?basic?research?findings?at?the?84th?American?Diabetes?Association?(ADA)?Annual?Scientific?Sessions.
Hua?Medicine?(the?"Company",?HKEx?stock?code:?2552)?announced?today?that?its?wholly?owned?subsidiary?Nanjing?AscendRare?Pharmaceutical?Technology?Co.,?Ltd.
Hua?Medicine?(the?"Company",?HKEx:?2552.HK)?announced?that?the?Company?has?officially?initiated?its?Phase?I?clinical?trial?of?its?2nd?generation?glucokinase?allosteric?activator?(2nd?Gen?GKA)?in?the?United?States,?with?the?successful?enrollment?of?the?first?patient.?
ir@huamedicine.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
滬公網(wǎng)安備 31011502013809號 Privacy Statement Terms of Use
